NCT02184624 - Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices | Biotech Hunter

Enrollment

569

Participants

Timeline

Start Date

August 28, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

ELLIPTA

Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.

DEVICE

DISKUS/ACCUHALER

Placebo inhaler with one blister strip containing lactose monohydrate.

DEVICE

MDI

Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).

DEVICE

TURBUHALER

Placebo inhaler containing lactose monohydrate.

DEVICE

HANDIHALER

Placebo inhaler containing lactose monohydrate in a capsule.

DEVICE

BREEZEHALER

Placebo inhaler containing lactose monohydrate in a capsule.

Trial Locations (8)

1311 RL

GSK Investigational Site, Almere Stad

6191 JW

GSK Investigational Site, Beek

7513 ER

GSK Investigational Site, Enschede

7694 AC

GSK Investigational Site, Kloosterhaar

7442 LS

GSK Investigational Site, Nijverdal

7207 AE

GSK Investigational Site, Zutphen

PO6 3LY

GSK Investigational Site, Portsmouth

SO16 6YD

GSK Investigational Site, Southampton